Format

Send to

Choose Destination
Nat Rev Neurosci. 2010 Dec;11(12):791-7. doi: 10.1038/nrn2935. Epub 2010 Nov 19.

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Author information

1
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health (NIH), Building 35, Room 1A116, MSC 3707, 35 Convent Drive, Bethesda, Maryland 20982-3707, USA. Cookson@mail.nih.gov

Abstract

Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene--leucine-rich repeat kinase 2 (LRRK2)--affect protein function, and I review recent evidence that LRRK2 mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.

PMID:
21088684
PMCID:
PMC4662256
DOI:
10.1038/nrn2935
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center